Cargando…

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma

The expression of CD47 on the cancer cell surface transmits “don’t eat me” signalling that not only inhibits phagocytosis of cancer cells by phagocytes but also impairs anti-cancer T cell responses. Here we report that oncogenic activation of ERK plays an important role in transcriptional activation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Fen, Jiang, Chen Chen, Yan, Xu Guang, Tseng, Hsin-Yi, Wang, Chun Yan, Zhang, Yuan Yuan, Yari, Hamed, La, Ting, Farrelly, Margaret, Guo, Su Tang, Thorne, Rick F., Jin, Lei, Wang, Qi, Zhang, Xu Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642493/ https://www.ncbi.nlm.nih.gov/pubmed/29050218 http://dx.doi.org/10.18632/oncotarget.17704

Ejemplares similares

Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922
por: Wang, Chun Yan, et al.
Publicado: (2016)

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
por: Lei, Fu Xi, et al.
Publicado: (2018)

Correction to: RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
por: Lei, Fu Xi, et al.
Publicado: (2019)

Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells
por: Liu, Yi Lun, et al.
Publicado: (2014)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
por: Jung, Thomas, et al.
Publicado: (2021)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Dual functions for OVAAL in initiation of RAF/MEK/ERK prosurvival signals and evasion of p27-mediated cellular senescence
por: Sang, Ben, et al.
Publicado: (2018)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Cylindromatosis Is Required for Survival of a Subset of Melanoma Cells
por: La, Ting, et al.
Publicado: (2020)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation
por: Liu, Lin, et al.
Publicado: (2020)

Growth hormone receptor promotes breast cancer progression via the BRAF/MEK/ERK signaling pathway
por: Zhu, Xiaojue, et al.
Publicado: (2020)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients
por: Yan, Chi, et al.
Publicado: (2022)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
por: Krepler, Clemens, et al.
Publicado: (2016)

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
por: Yin, Qing, et al.
Publicado: (2019)

Abl Kinase Regulation by BRAF/ERK and Cooperation with Akt in Melanoma
por: Jain, Aditi, et al.
Publicado: (2017)

Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials
por: Liu, Mengdong, et al.
Publicado: (2017)

Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma
por: Song, Chengli, et al.
Publicado: (2017)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
por: Zhang, Simeng, et al.
Publicado: (2023)

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels
por: Yuan, Long, et al.
Publicado: (2020)

MEK + CDK4 a regimen for non-BRAF V6000 melanoma
por: Sosman, Jeff
Publicado: (2015)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
por: Morales, Delphine, et al.
Publicado: (2021)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
por: Ismail, Rawa K., et al.
Publicado: (2022)

Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
por: Hui, Caressa, et al.
Publicado: (2022)

ERK5 is activated by oncogenic BRAF and promotes melanoma growth
por: Tusa, Ignazia, et al.
Publicado: (2018)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis
por: Chen, Peng, et al.
Publicado: (2017)

Corrigendum: Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma
por: Song, Chengli, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_svio9p5hf4sh9j87cv8o3cd4hn